JP2022500381A5 - - Google Patents
Info
- Publication number
- JP2022500381A5 JP2022500381A5 JP2021513254A JP2021513254A JP2022500381A5 JP 2022500381 A5 JP2022500381 A5 JP 2022500381A5 JP 2021513254 A JP2021513254 A JP 2021513254A JP 2021513254 A JP2021513254 A JP 2021513254A JP 2022500381 A5 JP2022500381 A5 JP 2022500381A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- alkyl
- optionally substituted
- kras
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024091743A JP2024133475A (ja) | 2018-09-10 | 2024-06-05 | 組み合わせ療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729169P | 2018-09-10 | 2018-09-10 | |
| US62/729,169 | 2018-09-10 | ||
| PCT/US2019/050224 WO2020055755A1 (en) | 2018-09-10 | 2019-09-09 | Combination therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091743A Division JP2024133475A (ja) | 2018-09-10 | 2024-06-05 | 組み合わせ療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500381A JP2022500381A (ja) | 2022-01-04 |
| JP2022500381A5 true JP2022500381A5 (enExample) | 2022-09-16 |
| JP7546549B2 JP7546549B2 (ja) | 2024-09-06 |
Family
ID=69776771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513254A Active JP7546549B2 (ja) | 2018-09-10 | 2019-09-09 | 組み合わせ療法 |
| JP2024091743A Pending JP2024133475A (ja) | 2018-09-10 | 2024-06-05 | 組み合わせ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091743A Pending JP2024133475A (ja) | 2018-09-10 | 2024-06-05 | 組み合わせ療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220040181A1 (enExample) |
| EP (2) | EP4552631A3 (enExample) |
| JP (2) | JP7546549B2 (enExample) |
| DK (1) | DK3849534T3 (enExample) |
| ES (1) | ES3017461T3 (enExample) |
| FI (1) | FI3849534T3 (enExample) |
| HR (1) | HRP20250480T1 (enExample) |
| HU (1) | HUE071715T2 (enExample) |
| LT (1) | LT3849534T (enExample) |
| PL (1) | PL3849534T3 (enExample) |
| PT (1) | PT3849534T (enExample) |
| RS (1) | RS66727B1 (enExample) |
| SI (1) | SI3849534T1 (enExample) |
| WO (1) | WO2020055755A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022500385A (ja) * | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EA202190749A1 (ru) * | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| WO2021043322A1 (zh) * | 2019-09-06 | 2021-03-11 | 正大天晴药业集团南京顺欣制药有限公司 | 氮杂环庚烷并嘧啶类衍生物及其医药用途 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| EP4041399A1 (en) | 2019-10-02 | 2022-08-17 | Tolremo Therapeutics AG | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| CN114555586B (zh) * | 2019-10-10 | 2023-06-23 | 信达生物制药(苏州)有限公司 | Krasg12c蛋白抑制剂及其制备方法和用途 |
| BR112022010278A2 (pt) | 2019-11-27 | 2022-10-04 | Turning Point Therapeutics Inc | Terapia combinada que envolve compostos macrocíclicos de diarila |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021219072A1 (zh) * | 2020-04-30 | 2021-11-04 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| CN113683616B (zh) * | 2020-05-18 | 2025-12-30 | 广州百霆医药科技有限公司 | Kras g12c突变蛋白抑制剂 |
| KR20230028798A (ko) * | 2020-06-25 | 2023-03-02 | 톨레모 테라퓨틱스 아게 | 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물 |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| IL307402A (en) | 2021-04-07 | 2023-12-01 | Tolremo Therapeutics Ag | The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer |
| CN113429405A (zh) * | 2021-06-10 | 2021-09-24 | 都创(上海)医药开发有限公司 | Mrtx849化合物的晶型及其制备方法和用途 |
| MX2024000357A (es) | 2021-07-07 | 2024-02-12 | Incyte Corp | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). |
| WO2023287896A1 (en) | 2021-07-14 | 2023-01-19 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| IL312381A (en) | 2021-11-05 | 2024-06-01 | Frontier Medicines Corp | KRAS G12C inhibitors |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN119607214B (zh) * | 2025-02-17 | 2025-06-20 | 四川大学华西医院 | Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE337312T1 (de) | 2001-07-03 | 2006-09-15 | Vertex Pharma | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
| US20040014676A1 (en) | 2001-07-09 | 2004-01-22 | Ramalinga Dharanipragada | SRC kinase inhibitors useful for treating osteoporosis |
| US20040248906A1 (en) | 2001-08-10 | 2004-12-09 | Donato Nicholas J | Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia |
| AU2003278383B2 (en) | 2002-11-04 | 2007-06-14 | Astrazeneca Ab | Quinazoline derivatives as Src tyrosine kinase inhibitors |
| WO2008054792A2 (en) | 2006-10-31 | 2008-05-08 | University Of Toledo | Na+/k+-atpase-specific peptide inhibitors/activators of src and src family kinases |
| US20100099710A1 (en) | 2007-04-19 | 2010-04-22 | Lene Jensen | Src family kinase inhibitors |
| CN104230901A (zh) | 2008-09-15 | 2014-12-24 | 加利福尼亚大学董事会 | 用于调节ire1、src和abl活性的方法和组合物 |
| MX353205B (es) | 2011-08-03 | 2018-01-08 | Univ Nat Taiwan | Agonistas de proteína-tirosina-fosfatasa-1 que contiene homología src-2 y métodos de tratamiento que usan los mismos. |
| US9090617B1 (en) | 2011-08-03 | 2015-07-28 | National Taiwan University | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
| CA2944198C (en) | 2013-04-26 | 2021-11-16 | Indiana University Research & Technology Corporation | Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2) |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| KR102444509B1 (ko) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| JP7327802B2 (ja) * | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
-
2019
- 2019-09-09 ES ES19858883T patent/ES3017461T3/es active Active
- 2019-09-09 WO PCT/US2019/050224 patent/WO2020055755A1/en not_active Ceased
- 2019-09-09 HR HRP20250480TT patent/HRP20250480T1/hr unknown
- 2019-09-09 DK DK19858883.2T patent/DK3849534T3/da active
- 2019-09-09 HU HUE19858883A patent/HUE071715T2/hu unknown
- 2019-09-09 EP EP25153820.3A patent/EP4552631A3/en active Pending
- 2019-09-09 PL PL19858883.2T patent/PL3849534T3/pl unknown
- 2019-09-09 SI SI201930915T patent/SI3849534T1/sl unknown
- 2019-09-09 PT PT198588832T patent/PT3849534T/pt unknown
- 2019-09-09 LT LTEPPCT/US2019/050224T patent/LT3849534T/lt unknown
- 2019-09-09 FI FIEP19858883.2T patent/FI3849534T3/fi active
- 2019-09-09 EP EP19858883.2A patent/EP3849534B1/en active Active
- 2019-09-09 RS RS20250386A patent/RS66727B1/sr unknown
- 2019-09-09 JP JP2021513254A patent/JP7546549B2/ja active Active
- 2019-09-09 US US17/275,175 patent/US20220040181A1/en not_active Abandoned
-
2024
- 2024-06-05 JP JP2024091743A patent/JP2024133475A/ja active Pending
-
2025
- 2025-03-18 US US19/082,614 patent/US20250213579A1/en active Pending